Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Mitochondrial genome variability: the effect on cellular functional activity

Authors Volobueva AS, Melnichenko AA, Grechko AV, Orekhov AN

Received 12 October 2017

Accepted for publication 7 December 2017

Published 9 February 2018 Volume 2018:14 Pages 237—245

DOI https://doi.org/10.2147/TCRM.S153895

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Hoa Le

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


Aleksandrina S Volobueva,1 Alexandra A Melnichenko,2 Andrey V Grechko,3 Alexander N Orekhov2,4

1Laboratory of Gene Therapy, Biocad Biotechnology Company, Saint-Petersburg, Strelnya, Russia; 2Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Russian Academy of Sciences, Moscow, Russia; 3Federal Scientific Clinical Center for Resuscitation and Rehabilitation, Moscow, Russia; 4Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow, Russia

Abstract: Mitochondria are the key players in cell metabolism, calcium homeostasis, and reactive oxygen species (ROS) production. Mitochondrial genome alterations are reported to be associated with numerous human disorders affecting nearly all tissues. In this review, we discuss the available information on the involvement of mitochondrial DNA (mtDNA) mutations in cell dysfunction.

Keywords: mitochondria, mutation, apoptosis, reactive oxygen species, ATP, electron transfer chain

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]